36P Preliminary results of bulumtatug fuvedotin (BFv, 9MW2821) in combined with toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a phase Ib/II clinical study
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation nectin-4 antibody-drug conjugate (ADC) has demonstrated promising antitumor activity and is well tolerated in patients with cervical cancer (CC). Here, we present preliminary efficacy and safety results from an open-label, multicenter, single-arm clinical study combining BFv with Toripalimab in patients with recurrent or metastatic CC.
Authors
- Hongyun Zhao (ORCID: https://orcid.org/0000-0002-1251-3888)
- L. Wang
- H. Yang
- X Wu
- T. Wu
- H. Lou
- L. He
- R. Guo
- Y. Wang
- S. Wang
- P. Wang
- J. Ni
- P. Xie
- Y. Tang
- M. Feng
Institutions
- Fujian Medical University (CN)
- Kunming Medical University (CN)
- Bioscience Research (US)
- Fudan University Shanghai Cancer Center (CN)
- Zhejiang Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- Jiangxi Maternal and Child Health Hospital (CN)
- International Peace Maternity & Child Health Hospital (CN)
- The First People's Hospital of Changde (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Henan Cancer Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- Chongqing Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Second People’s Hospital of Yibin (CN)
- Shandong First Medical University (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108062
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00